HC Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals, Keeps $38 Target
HC Wainwright reiterated its Buy rating and $38.00 price target on Syndax Pharmaceuticals. The target implies 129.6% upside from the October 12 close of $16.55.
Story updates
11:09:29 AM UTC
SquawkNews
Syndax Pharmaceuticals Price Target Maintained With a $38.00/Share by HC Wainwright & Co.